Close Menu
  • Tech Insights
  • Laptops
  • Mobiles
  • Gaming
  • Apps
  • Money
  • Latest in Tech
Facebook X (Twitter) Instagram
Facebook X (Twitter) Instagram
TechzLab – Tech News, Gadgets, Mobile & IT UpdatesTechzLab – Tech News, Gadgets, Mobile & IT Updates
  • Tech Insights
  • Laptops
  • Mobiles
  • Gaming
  • Apps
  • Money
  • Latest in Tech
TechzLab – Tech News, Gadgets, Mobile & IT UpdatesTechzLab – Tech News, Gadgets, Mobile & IT Updates
Home » The Crackdown on Compounded GLP-1 Meds Has Begun
Tech Insights

The Crackdown on Compounded GLP-1 Meds Has Begun

adminBy adminOctober 10, 2024No Comments3 Mins Read
Facebook Twitter Pinterest LinkedIn Tumblr Email
Share
Facebook Twitter LinkedIn Pinterest Email

Eli Lilly has sent cease-and-desist letters to hundreds of compounding pharmacies, telehealth companies, and medical spas making and selling “compounded” versions of tirzepatide. This hawkish legal strategy indicates that a new phase of the GLP-1 gold rush has begun—a crackdown against any entity selling non-name-brand medications.

Tirzepatide, the active ingredient in Eli Lilly’s diabetes drug Mounjaro and weight-loss medication Zepbound, was on the US Food and Drug Administration’s shortage list from December 2022 until October 2, 2024. When drugs in the US go into shortage, pharmacists, doctors, and licensed outsourcing facilities are permitted to “compound” copies to make sure patients have access to medicine they need. With so many potential patients eager to get on GLP-1 medications, the shortage of both tirzepatide and semaglutide (the active ingredient in Ozempic and Wegovy) left a huge opening in the market. Usually, pharmaceutical companies producing blockbuster drugs don’t have to worry about competition until their patents expire. But the shortages meant that it was legal for compounders to produce their own GLP-1 dupes—which they did, at an unprecedented volume. Major telehealth clinics jumped in to sell these products online at a fraction of the price of their name-brand counterparts. While there is no definitive accounting for how many patients are taking compounded GLP-1 meds, Alliance for Pharmacy Compounding CEO Scott Brunner tells WIRED that he estimates that the number is in the millions.

This isn’t the first legal action Eli Lilly has taken regarding compounded tirzepatide. The pharmaceutical behemoth has filed a number of lawsuits alleging deceptive advertising from sellers promoting “generic tirzepatide” or “generic Mounjaro” and referring to their compounded products as “FDA-approved.” (Unlike standard name-brand and generic pharmaceutical drugs, compounded drugs are not subject to the FDA’s approval processes before hitting the market.) But this represents a major escalation of Lilly’s fight against what it views as knockoffs.

At least one of the cease-and-desist letters is to a virtual telehealth clinic selling an oral version of tirzepatide, sold in pill form rather than as an injectable medication. Eli Lilly specifically accused this oral tirzepatide seller of “experimenting” on its customers, noting that the US Food and Drug Administration has not approved any oral tirzepatide medications.

Eli Lilly also targeted at least one weight-loss clinic promoting its tirzepatide products on Reddit, which has several active communities devoted to compounded GLP-1 medications.

In the wake of the shortage ending, some telehealth companies offering the medication encouraged patients to order expanded supplies of the drugs, meant to tide them over for multiple months. In at least one of the cease-and-desist letters, Eli Lilly noted that a clinic had started offering “extended prescriptions,” a practice Lilly alleges is an “unlawful attempt to circumvent the shortage.”

The end of the tirzepatide shortage has created a fraught moment for many patients taking the compounded version of the drug. As WIRED recently reported, many of these patients are concerned that they will not be able to afford or access the name-brand versions of their medication. While Eli Lilly recently introduced a new, cheaper version of Mounjaro and Zepbound (which comes in a vial instead of an injector pen), the price per month, which ranges from $400 to $550 depending on dosage, is still significantly higher than many of the compounded vials on offer.

Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
admin
  • Website

Related Posts

2 Meteor Showers Are Peaking on the Same Night in July. How to Catch a Glimpse

July 18, 2025

Fighting AI with AI, finance firms prevented $5 million in fraud – but at what cost?

July 17, 2025

Vivo V60 India Launch Date Tipped; Said to Be First Global Model to Arrive With OriginOS

July 16, 2025

Comments are closed.

Latest
  • Exclusive: Benchmark backs AI-code review startup Greptile, valued at $180M, sources say July 19, 2025
  • The Big Summer Warhammer Preview Show 2025: Everything Announced July 18, 2025
  • Redmi 15C Price and Specifications Surface Online Via Online Retailer July 18, 2025
  • ChatGPT Agent shows that there’s a whole new world of AI security threats on the way we need to worry about July 18, 2025
  • Can't Brighten Up Your Screen? Here's How to Fix Your Windows 10 Dim Dilemma – Lifewire July 18, 2025
We are social
  • Facebook
  • Twitter
  • Pinterest
  • Instagram
  • YouTube
  • Vimeo

Subscribe to Updates

Get the latest creative news from Techzlab.

Tags
Apple artificial intelligence avp ChatGPT cybersecurity daniel ek data centers doge Donald Trump Elon Musk evergreens EVs Exclusive Fine funding round Google Google Search Grok In Brief India lawsuit low code development lucky Meta Microsoft neobanks Openai Perplexity Pinterest Proton remittance Rippling robotics Scales to Sequioa slate auto SMBs social media SpaceX Spotify TechCrunch All Stage 2025 Tesla Trump Administration Voice Ai Y Combinator
Archives
Quick Link
  • Apps (252)
  • From the Editor (3)
  • Gaming (251)
  • Laptops (252)
  • Latest in Tech (252)
  • Mobiles (253)
  • Money (77)
  • Tech Insights (252)
Don't miss

2 Meteor Showers Are Peaking on the Same Night in July. How to Catch a Glimpse

July 18, 2025

Fighting AI with AI, finance firms prevented $5 million in fraud – but at what cost?

July 17, 2025

Vivo V60 India Launch Date Tipped; Said to Be First Global Model to Arrive With OriginOS

July 16, 2025
Follow us
  • Facebook
  • Twitter
  • Pinterest
  • Instagram
  • YouTube
  • Vimeo
© 2025 Techzlab.com Designed and Developed by WebExpert.
  • Home
  • From the Editor
  • Money
  • Privacy Policy
  • Contact

Type above and press Enter to search. Press Esc to cancel.